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Abstract: The β-carbonic anhydrase (CA, EC 4.2.1.1) from the pathogenic protozoan Entamoeba
histolytica, EhiCA, was investigated for its activation with a panel of natural and non-natural amino
acids and amines. EhiCA was potently activated by D-His, D-Phe, D-DOPA, L- and D-Trp, L- and
D-Tyr, 4-amino-L-Tyr, histamine and serotonin, with KAs ranging between 1.07 and 10.1 µM. The best
activator was D-Tyr (KA of 1.07 µM). L-Phe, L-DOPA, L-adrenaline, L-Asn, L-Asp, L-Glu and L-Gln
showed medium potency activation, with KAs of 16.5–25.6 µM. Some heterocyclic- alkyl amines, such
as 2-pyridyl-methyl/ethyl-amine and 4-(2-aminoethyl)-morpholine, were devoid of EhiCA activating
properties with KAs > 100 µM. As CA activators have poorly been investigated for their interaction
with protozoan CAs, our study may be relevant for an improved understanding of the role of this
enzyme in the life cycle of E. histolytica.
Keywords: Entamoeba histolytica; carbonic anhydrase; metalloenzymes; protozoan; amine; amino
acid; activator
1. Introduction
Recently, we have reported [1,2] the cloning, purification and characterization of a β-carbonic
anhydrase (CA, EC 4.2.1.1) present in the genome of the pathogenic protozoan Entamoeba histolytica,
the etiological agents provoking amebiasis, an endemic disease in developing countries and also
affecting travelers returning from risk zones [3–5]. In addition, invasive forms of E. histolytica infection
were reported to lead to liver cysts, associated frequently with complications such as pleural effusion
due to the rupture of the cysts as well as dissemination to extra-intestinal organs, e.g., the brain or
pericardium, which occasionally may have fatal consequences [3,6]. In the previous work [1,2] we also
investigated the inhibition profile of the new enzyme (nominated EhiCA) with the main classes of
CA inhibitors (CAIs) [7–10], the sulfonamides and the inorganic anions [11–14]. Our main scope was
to identify agents that by interference with the activity of this enzyme, might lead to anti-infectives
with a novel mechanism of action, considering the fact that many CAs are essential in the life cycle
of microorganisms belonging to the bacteria, fungal or protozoan domains [15–17]. As β-CAs are
not present in mammals [18,19], effective EhiCA inhibitors may represent an alternative therapeutic
option for this protozoan infection. In fact, in the previous work we have shown that inhibition of
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other protozoan CAs, such as the β-class enzyme from Leishmania donovani [20,21] or the α-CA from
Trypanosoma cruzi [20,22,23], has important antiparasitic effects in vitro and in vivo [21].
Indeed, various pathogenic organisms belonging to the bacteria, fungal or protozoan domains
encode for CAs, which have been investigated in some detail ultimately, in the search of anti-infectives
with a diverse mechanism of action [7–10,14–23]. CAs catalyze the reaction between CO2 and water,
with formation of bicarbonate (HCO3-) and protons (H+), and are highly effective catalysts, among the
most efficient known so far in nature [7–10]. CAs are involved in various biochemical and metabolic
processes, among which are acid-base homeostasis, respiration, biosynthesis of various metabolites
(urea, glucose, fatty acids, carbamoyl phosphate), electrolytes secretion, etc. [7–12]. Seven distinct
CA families are known to date, the α, β, γ, δ, ζ, η and θ class CAs, which are widespread all over
the phylogenetic tree, from simple organisms, such as bacteria and Archaea, to more complex ones,
such as vertebrates [7–10,24–28]. These diverse CA genetic families do not share significant sequence
homology or structural identity, being an interesting example of convergent evolution at the molecular
level [7–10]. In humans, as in many other vertebrates, only α-CAs are present, and their inhibition
has been exploited from the pharmacological viewpoint for decades, for drugs such as diuretics [29],
anticonvulsants [29,30], antiobesity [30] and more recently, antitumor agents [31]. However, these
enzymes may also be activated [32] but the CA activators (CAAs) have seen fewer applications up
until now. However, recent studies [33] pointed out to the possible application of CAAs targeting
human enzymes for the enhancement of cognition. The nonvertebrate CAs were on the other hand
only in the last few years investigated in some detail [34–37]. Here we report the first activation study
of the β-CA from E. histolytica with a panel of amines and amino acid derivatives. As CAAs have
poorly been investigated for their interaction with protozoan CAs, our study may be relevant for an
improved understanding of the role of this enzyme in the life cycle of E. histolytica.
2. Results and Discussion
The catalytic activity of the recombinant EhiCA (for the CO2 hydration reaction), has been recently
reported [1,2], being measured by using a stopped flow technique [38]. EhiCA showed a significant
catalytic activity for the physiologic, CO2 hydration reaction, with the following kinetic parameters:
kcat = 6.7 × 105 s−1 and kcat/Km = 8.9 × 107 M−1 × s−1. Thus, EhiCA is 1.8 times more effective
as a catalyst compared to the slow human (h) isoform hCA I (considering the kcat/Km values) or
3.35 times more effective than hCA I (considering only the kinetic constant kcat) [1,2]. EhiCA activity
was also inhibited by the standard, clinically used sulfonamide CA inhibitor acetazolamide (AZA,
5-acetamido-1,3,4-thiadiazole-2-sulfonamide), with a KI of 509 nM (data not shown here) [1,2].
Similar to all β-CAs investigated to date, EhiCA has a catalytically crucial zinc ion and its
conserved protein ligands, which for this enzyme are: Cys50, His103 and Cys106 [1,2]. The fourth
metal ion ligand is a water molecule/hydroxide ion, which acts as nucleophile in the catalytic cycle
(Equation (1) below). A catalytic dyad constituted by the pair Asp52-Arg54 [1,2], conserved in all
enzymes belonging to the β-class is also present in EhiCA, presumably with the role to enhance
the nucleophilicity of the zinc-coordinated water molecule [18–20]. However, the rate-determining
step for many CAs is the generation of the nucleophilic species of the enzyme, represented by
Equation (2) below:
H2O
EZn2+—OH− + CO2 ⇔ EZn2+—HCO3- ⇔ EZn2+—OH2 + HCO3 (1)
EZn2+— -OH2 ⇔ EZn2+—OH− + H+ (2)
In most CAs, this step (Equation (2)) is assisted by amino acid residues from the active
site [32], becoming an intramolecular step (instead of an intermolecular one), which is favored
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thermodynamically. Furthermore, the activators (CAAs) may participate in this step, as outlined
in Equation (3):
EZn2+— -OH2 + A⇔ [EZn2+— -OH2 − A]⇔ [EZn2+—OH− − AH+]⇔ EZn2+—OH− + AH+ (3)
enzyme - activator complexes
The enzyme forms with the activator complexes (E-A complexes, where E stands for enzyme and
A for activator), in which the proton transfer step from the zinc-coordinated water to the environment
is intramolecular and thus, more efficient than the corresponding intermolecular process shown
schematically in Equation (2) [32]. In fact, X-ray crystal structures are available for many CAs to which
activators are bound within the active site [32,39–41], but only for α-class enzymes these structures
have been reported to date. The activator binding site for the α-CAs is situated at the entrance of the
active site cavity not far away from His64, which acts as proton shuttle residue in the process described
by Equation (2) [32,39–41].
We have performed detailed kinetic measurements of EhiCA activity in the presence of amine
and amino acid activators (Figure 1), such as for example L-Trp (Table 1). Data of Table 1 show that the
presence of L-Trp does not change the KM, both for the α-class enzymes hCA I/II as well as the β-CA,
EhiCA, investigated here. Interestingly, it has an effect on the kcat, which at 10-µM concentration of
activator leads to a 2.83 times enhancement of the kinetic constant for the protozoan enzyme, from 6.7
× 105 s−1 to 1.9 × 106 s−1 (Table 1).
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Table 1. Activation of human carbonic anhydrase (hCA) isozymes I, II, and EhiCA with L-Trp at 25 ◦C
for the CO2 hydration reaction [38].
Isozyme kcat * KM * (kcat)L-Trp ** KA *** (µM)
(s−1) (mM) (s−1) L-Trp
hCA I a 2.0 × 105 4.0 3.4 × 105 44.0
hCA II a 1.4 × 106 9.3 4.9 × 106 27.0
LdCA 9.35 × 105 15.8 1.9 × 106 4.02
EhiCA b 6.7 × 105 7.5 1.9 × 106 5.24
* Observed catalytic rate without activator. KM values in the presence and the absence of activators were the
same for the various CAs (data not shown).; ** Observed catalytic rate in the presence of 10 µM activator; *** The
activation constant (KA) for each enzyme was obtained by fitting the observed catalytic enhancements as a function
of the activator concentration [41]. Mean from at least three determinations by a stopped-flow, CO2 hydrase method
[38]. Standard errors were in the range of 5–10% of the reported values (data not shown); a Human recombinant
isozymes, from ref. [32]; b Protozoan recombinant enzyme, this work.
In order to obtain an activation profile of EhiCA with a wide range of amino acid and amine
activators of types 11–24, we performed dose response curves of the activation of EhiCA in the presence
of increasing concentrations of activators, in order to determine the activation constants KA-s (see
Materials and Methods for details). We included in our study the amino acids and amines which were
investigated as activators of CAs belonging to various classes from diverse organisms [32–37,40–42].
These activation data are reported in Table 2, in which, for comparison reasons, the activation of
the human isoforms hCA I and II and of the protozoan β-CA from Leishmania donovani chagasi are
also presented.
Table 2. Activation constants of hCA I, hCA II and the protozoan enzymes LdcCA (L. donovani chagasi)
and EhiCA (E. histolytica) with amino acids and amines 1–24. Data for hCA I and II are from [32] and
for LdcCA from [42].
No. Compound KA (mM) *
hCA I a hCA II a LdcCA b EhiCA c
1 L-His 0.03 10.9 8.21 78.7
2 D-His 0.09 43 4.13 9.83
3 L-Phe 0.07 0.013 9.16 16.5
4 D-Phe 86 0.035 3.95 10.1
5 L-DOPA 3.1 11.4 1.64 16.6
6 D-DOPA 4.9 7.8 5.47 4.05
7 L-Trp 44 27 4.02 5.24
8 D-Trp 41 12 6.18 4.95
9 L-Tyr 0.02 0.011 8.05 4.52
10 D-Tyr 0.04 0.013 1.27 1.07
11 4-H2N-L-Phe 0.24 0.15 15.9 8.12
12 Histamine 2.1 125 0.74 7.38
13 Dopamine 13.5 9.2 0.81 30.8
14 Serotonin 45 50 0.62 4.94
15 2-Pyridyl-methylamine 26 34 0.23 >100
16 2-(2-Aminoethyl)pyridine 13 15 0.012 >100
17 1-(2-Aminoethyl)-piperazine 7.4 2.3 0.009 43.8
18 4-(2-Aminoethyl)-morpholine 0.14 0.19 0.94 >100
19 L-Adrenaline 0.09 96 4.89 25.6
20 L-Asn 11.3 >100 4.76 23.8
21 L-Asp 5.2 >100 0.3 23.9
22 L-Glu 6.43 >100 12.9 25.5
23 D-Glu 10.7 >100 0.082 30.3
24 L-Gln >100 >50 2.51 20.1
* Mean from three determinations by a stopped-flow, CO2 hydrase method [38]. Standard errors were in the range
of 5–10% of the reported values (data not shown). a Human recombinant isozymes, from ref. [32]; b Protozoan
recombinant enzyme, from ref. [42]; c This work.
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The structure–activity relationship (SAR) for the activation of EhiCA with compounds 1–24
revealed the following observations:
(i) Some heterocyclic-alkyl amines, such as 2-pyridyl-methyl/ethyl-amine 15, 16 and
4-(2-aminoethyl)-morpholine, were devoid of EhiCA activating properties up to 100 µM
concentration of activator in the assay system. All these compounds are structurally related,
possessing a heterocyclic ring and aminomethyl/aminoethyl moieties in their molecules.
(ii) L-His, dopamine, 1-(2-aminoethyl)-piperazine and D-Glu were poor EhiCA activators, with
activation constants ranging between 30.3 and 78.7 µM (Table 2). There is no strong structural
correlation between these three compounds.
(iii) Many of the compounds investigated here showed medium potency efficacy as EhiCA activators,
with KAs ranging between 16.5 and 25.6 µM. They include L-Phe, L-DOPA, L-adrenaline, L-Asn,
L-Asp, L-Glu and L-Gln. It may be observed that there are no remarkable differences of activity
between the pairs L-Asp/L-Asn and L-Glu/L-Gln, whereas D-Glu was more ineffective compared
to L-Glu. This is in fact the exception, as for other L-/D-enantiomeric amino acids investigated
here, the D-enantiomer was the most effective activator (see later in the text).
(iv) Effective EhiCA activating properties were detected for the following amino acids/amines: D-His,
D-Phe, D-DOPA, L- and D-Trp, L- and D-Tyr, 4-amino-L-Tyr, histamine and serotonin, which
showed KAs ranging between 1.07 and 10.1 µM. The best activator was D-Tyr (KA of 1.07 µM).
In fact for all aromatic amino acids investigated here, the D-enantiomer was more effective as
EhiCA activator compared to the corresponding L-enantiomer. For the Phe-Tyr-DOPA subseries,
the activity increased by hydroxylation of the Phe, achieving a maximum for Tyr and then
slightly decreased with the introduction of an additional OH moiety in DOPA, but always the
D-enantiomers were better activators compared to the L-ones. The loss of the carboxyl moiety,
such as in histamine and serotonin, did not lead to important changes of activity compared to
the corresponding D-amino acids, but in the case of dopamine, the activating efficacy was much
lower compared to those of both L- and D-DOPA.
(v) The activation profile of EhiCA with amino acid and amine derivatives is rather different from
those of other CAs, among which the protozoan β-CA from Leishmania donovani chagasi (LdcCA)
or the α-class human CAs, isoforms hCA I and II. For example 17 was a nanomolar activator for
LdcCA whereas its affinity for EhiCA was of only 43.8 µM. For the moment, no EhiCA-selective
activators were detected.
3. Materials and Methods
3.1. EhiCA Production and Purification
The protocol described in [1,2] has been used to obtain purified recombinant EhiCA. All activators
were commercially available from Sigma-Aldrich (Milan, Italy) and were of the highest purity available.
3.2. CA activity and Activation Measurements
An Sx.18Mv-R Applied Photophysics (Oxford, UK) stopped-flow instrument has been used to
assay the catalytic activity of various CA isozymes for CO2 hydration reaction [38]. Phenol red (at a
concentration of 0.2 mM) was used as indicator, working at the absorbance maximum of 557 nm, with
10 mM Hepes (pH 7.5, for α-CAs) or TRIS (pH 8.3, for β-CAs) as buffers, 0.1 M NaClO4 (for maintaining
constant ionic strength), following the CA-catalyzed CO2 hydration reaction for a period of 10 s at 25
◦C. The CO2 concentrations ranged from 1.7 to 17 mM for the determination of the kinetic parameters
and inhibition constants. For each activator at least six traces of the initial 5–10% of the reaction
have been used for determining the initial velocity. The uncatalyzed rates were determined in the
same manner and subtracted from the total observed rates. Stock solutions of activators (at 0.1 mM)
were prepared in distilled-deionized water and dilutions up to 1 nM were made thereafter with
the assay buffer. Enzyme and activator solutions were pre-incubated together for 15 min prior to
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assay, in order to allow for the formation of the enzyme–activator complexes. The activation constant
(KA), defined similarly with the inhibition constant KI, can be obtained by considering the classical
Michaelis–Menten equation (Equation (4)), which has been fitted by nonlinear least squares by using
PRISM 3:
v = vmax/{1 + (KM/[S]) (1 + [A]f/KA)} (4)
where [A]f is the free concentration of activator.
Working at substrate concentrations considerably lower than KM ([S] << KM), and considering
that [A]f can be represented in the form of the total concentration of the enzyme ([E]t) and activator
([A]t), the obtained competitive steady-state equation for determining the activation constant is given
by Equation (5):
v = v0 · KA/{KA + ([A]t − 0.5{([A]t + [E]t + KA) − ([A]t + [E]t + KA)2 − 4[A]t · [E]t)1/2}} (5)
where v0 represents the initial velocity of the enzyme-catalyzed reaction in the absence of activator [32,41,42].
4. Conclusions
We report the first activation study of the β-CA from the protozoan parasite Entamoeba histolytica,
EhiCA, with a panel of amino acids and amines, some of which are important autacoids. The enzyme
was potently activated by D-His, D-Phe, D-DOPA, L- and D-Trp, L- and D-Tyr, 4-amino-L-Tyr,
histamine and serotonin, with KAs ranging between 1.07 and 10.1 µM. The best activator was
D-Tyr (KA of 1.07 µM). L-Phe, L-DOPA, L-adrenaline, L-Asn, L-Asp, L-Glu and L-Gln showed
medium potency activation, with KAs of 16.5–25.6 µM. Some heterocyclic-alkyl amines, such as
2-pyridyl-methyl/ethyl-amine and 4-(2-aminoethyl)-morpholine, were devoid of EhiCA activating
properties with KAs > 100 µM. The X-ray crystal structure of this enzyme is not known for the moment,
and in addition, no adducts of other parasite enzymes complexed with activators are available so far in
order to rationalize our results. However, as CAAs have poorly been investigated for their interaction
with protozoan CAs, our study may be relevant for an improved understanding of the role of this
enzyme in the life cycle of E. histolytica.
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